Feb 5, 2026
what are cost-benefit ratios of prescibing habitRibociclib, palbociclib and abemaciclib
Real-world and modelled analyses paint a mixed picture: often shows lower per‑patient medical costs versus in claims data, while multiple models conclude that adding palbociclib or to endocrine therap...